Amendments to the Claims:

The Claim Listing below will replace all prior version of the claims in the application:

Claim Listing

1. (Original) A compound having the formula:



I

or



II

,

or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof,

wherein

T is a 14-, 15-, or 16-membered macrolide connected via a macrocyclic ring carbon atom;

R^1 and R^3 independently are selected from the group consisting of: (a) H, (b) a C_{1-6} alkyl group, (c) a C_{2-6} alkenyl group, (d) a C_{2-6} alkynyl group, (e) $-C(O)R^5$, (f) $-C(O)OR^5$, (g) $-C(O)-NR^4R^4R^4R^4$, (h) $-C(S)R^5$, (i) $-C(S)OR^5$, (j) $-C(O)SR^5$, or (k) $-C(S)-NR^4R^4R^4R^4$;

R^2 is hydrogen or $-OR^{12}$;

D is selected from the group consisting of:

(a) a single bond, (b) a C_{1-6} alkyl group, (c) a C_{2-6} alkenyl group; (d) a C_{2-6} alkynyl group; (e) $-C(O)-X-$, (f) $-C(O)O-X-$, (g) $-C(O)NR^4R^4-X-$,

(h) $-C(=NR^4)-X-$, (i) $-C(=NR^4)O-X-$, (j) $-C(=NR^4)N-X-$,

(k) $-SO_2-X-$, (l) $-C(NR^4)NR^4-X-$, (m) $-C(S)-X-$,

(n) $-C(S)NR^4-X-$, (o) $-C(NR^4)S-X-$, or (p) $-C(O)S-X-$, wherein

i) 0-2 carbon atoms in any of (b)–(d) of D immediately above optionally is replaced by a moiety selected from the group consisting of O, $S(O)_p$, and NR^4,

ii) each of the groups (b)–(d) immediately above optionally is substituted with one or more R^5 groups,

iii) alternatively when R^5 is present as an optional substituent on (b)-(d), R^3 and R^5 can be taken together with the atoms to which they are attached to form a 3-7 membered ring, and

iv) X is selected from the group consisting of (aa) a C_{1-6} alkyl group, (bb) a C_{2-6} alkenyl group, or (cc) a C_{2-6} alkynyl group, wherein each of groups (aa)–(cc) optionally is substituted with one or more R^5 groups;

F is selected from the group consisting of:

(a) a single bond, (b) a C_{1-6} alkyl group, (c) a C_{2-6} alkenyl group, (d) a C_{2-6} alkynyl group, wherein

i) 0-2 carbon atoms in any of (b)–(d) of F immediately above optionally is replaced by a moiety selected from the group consisting of O, $S(O)_p$, and NR^4,

ii) any of (b)–(d) of F immediately above optionally is substituted with one or more R^5 groups, and

iii) any of (b)–(d) of F immediately above optionally is substituted with C_{1-6} alkyl-R^5 groups;

E is selected from the group consisting of:

(a) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

(b) a 3-10 membered saturated, unsaturated, or aromatic carbocycle,

(c) a –W–[3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur],

(d) a –W–[3-10 membered saturated, unsaturated, or aromatic carbocycle],

(e) –C(O)–, (f) –C(O)O–, (g) –C(O)NR^4–, (h) –C(=NR^4)–,

(i) –C(=NR^4)O–, (j) –C(=NR^4)NR^4–, (k) –OC(O)–, (l) –OC(O)O–,

(m) –OC(O)NR^4–, (n) –NR^4C(O)–, (o) –NR^4C(O)O–,

(p) $-NR^4C(O)NR^4-$, (q) $-NR^4C(=NR^4)NR^4-$, (r) $-S(O)_p-$,
(s) $-NR^4S(O)_2-$, (t) $-S(O)_2NR^4-$, (u) $-C(N-OR^4)-$, (v) $-CH_2-$,
(w) $-C(N-NR^4R^4)-$, (x) $-C(S)NR^4-$, (y) $-NR^4C(S)-$, (z) $-C(S)O-$, or
(aa) $-OC(S)-$, wherein

i) any of (a)-(d) immediately above optionally is substituted with one or more R^5 groups; and

ii) W is selected from the group consisting of:
(aa) $-OCO-$, (bb) $-OC(O)O-$, (cc) $-OC(O)NR^4-$,
(dd) $-NR^4C(O)O-$, (ee) $-OCNOR^4-$,
(ff) $-NR^4-C(O)O-$, (gg) $-C(S)(NR^4)-$, (hh) $-NR^4-$,
(ii) $-OC(S)O-$, (jj) $-OC(S)NR^4-$, (kk) $-NR^4C(S)O-$, (ll) $-OC(S)NOR^4-$, (mm) $-C(S)O-$, (nn)$-$,$OC(S)-$, (oo) $-C(O)-$, (pp) $-C(O)O-$, (qq) $-C(O)NR^4-$, (rr) $-C(=NR^4)-$,
(ss) $-C(=NR^4)O-$, (tt) $-C(=NR^4)NR^4-$, (uu) $-OC(O)-$, (vv) $-OC(O)O-$, (ww) $-OC(O)NR^4-$, (xx) $-NR^4C(O)-$, (yy) $-NR^4C(O)O-$,
(zz) $-NR^4C(O)NR^4-$, (aaa) $-NR^4C(=NR^4)NR^4-$, (bbb) $-S(O)_p-$, (ccc) $-NR^4S(O)_2-$, (ddd) $-S(O)_2NR^4-$, (eee) $-C(N-OR^4)-$, (fff) $-C(N-NR^4R^4)-$, (ggg) $-C(S)NR^4-$, or (hhh) $-NR^4C(S)-$;

G is selected from the group consisting of: (a) B′ and (b) B′-Z-B″, wherein

i) each B′ and B″ is independently selected from the group consisting of (aa) an aryl group, (bb) a heteroaryl group, (cc) a biaryl group, (dd) a fused bicyclic or tricyclic saturated, unsaturated or aromatic ring system optionally containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (ee) a 3-10 membered saturated or unsaturated heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (ff) a 3-10 membered saturated, or unsaturated carbocycle, wherein each (aa)-(ff) optionally is substituted with one or more R^{11} groups; and

ii) Z is selected from the group consisting of

(aa) a single bond, (bb) a C_{1-2} alkyl group, (cc) a C_2 alkenyl group, (dd) a C_2 alkynyl group, (ee) –C(O)–, (ff) –C(O)O–, (gg) –C(O)NR^4–, (hh) –C(=NR^4)–, (ii) –C(=NR^4)O–, (jj) –C(=NR^4)NR^4–, (kk) –$S(O)_p$–, (ll) –OC(O)– ,(mm) –C(S)–, (nn) –C(S)NR^4–, (oo) –C(NR^4)S–, (pp) –C(O)S–, (qq) –O–, (rr) –NR^4–, (ss) –NR^4C(O)–, (tt) –OC(NR^4)–, (uu) –NC(NR^4)–, (vv) –C(S)O–, (ww) –SC(O)–, or (xx) –OC(S)–;

R^4, at each occurrence, independently is selected from the group consisting of:

(a) H, (b) a C_{1-6} alkyl group, (c) a C_{2-6} alkenyl group, (d) a C_{2-6} alkynyl group, (e) a C_{6-10} saturated, unsaturated, or aromatic carbocycle, (f) a 3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (g) –C(O)–C_{1-6} alkyl, (h) –C(O)–C_{2-6} alkenyl, (i) –C(O)–C_{2-6} alkynyl, (j) –C(O)–C_{6-10} saturated, unsaturated, or aromatic carbocycle, (k) –C(O)–3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (l) –C(O)O–C_{1-6} alkyl, (m) –C(O)O–C_{2-6} alkenyl, (n) –C(O)O–C_{2-6} alkynyl,
(o) –C(O)O–C_{6-10} saturated, unsaturated, or aromatic carbocycle, p) –C(O)O–3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and q) –C(O)NR^6R^6,

wherein any of (b)–(p) optionally is substituted with one or more R^5 groups, alternatively, NR^4R^4 forms a 3-7 membered saturated, unsaturated or aromatic ring including the nitrogen atom to which the R^4 groups are bonded, wherein said ring is optionally substituted at a position other than the nitrogen atom to which the R^4 groups are bonded, with one or more moieties selected from the group consisting of O, $S(O)_p$, N, and NR^8;

R^5 is selected from the group consisting of:

(a) R^7, (b) a C_{1-8} alkyl group, (c) a C_{2-8} alkenyl group, (d) a C_{2-8} alkynyl group, (e) a C_{3-12} saturated, unsaturated, or aromatic carbocycle, and (f) a 3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, or two R^5 groups,

when present on the same carbon atom can be taken together with the carbon atom to which they are attached to form a spiro 3-6 membered carbocyclic ring or heterocyclic ring containing one or more heteroatoms selected form the group consisting of nitrogen, oxygen, and sulfur;

wherein any of (b)–(f) immediately above optionally is substituted with one or more R^7 groups;

R^6, at each occurrence, independently is selected from the group consisting of:

(a) H, (b) a C_{1-6} alkyl group, (c) a C_{2-6} alkenyl group, (d) a C_{2-6} alkynyl group, (e) a C_{3-10} saturated, unsaturated, or aromatic carbocycle, and (f) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of (b)–(f) optionally is substituted with one or more moieties selected from the group consisting of:

(aa) a carbonyl group, (bb) a formyl group, (cc) F, (dd) Cl, (ee) Br, (ff) I, (gg) CN, (hh) NO_2, (ii) $-OR^8$,

(jj) $-S(O)_pR^8$, (kk) $-C(O)R^8$, (ll) $-C(O)OR^8$,

(mm) $-OC(O)R^8$, (nn) $-C(O)NR^8R^8$,

(oo) $-OC(O)NR^8R^8$, (pp) $-C(=NR^8)R^8$,

(qq) $-C(R^8)(R^8)OR^8$, (rr) $-C(R^8)_2OC(O)R^8$,

(ss) $-C(R^8)(OR^8)(CH_2)_rNR^8R^8$, (tt) $-NR^8R^8$,

(uu) $-NR^8OR^8$, (vv) $-NR^8C(O)R^8$,

(ww) $-NR^8C(O)OR^8$, (xx) $-NR^8C(O)NR^8R^8$,

(yy) $-NR^8S(O)_rR^8$, (zz) $-C(OR^8)(OR^8)R^8$,

(ab) $-C(R^8)_2NR^8R^8$, (ac) $=NR^8$,

(ad) $-C(S)NR^8R^8$, (ae) $-NR^8C(S)R^8$,

(af) $-OC(S)NR^8R^8$, (ag) $-NR^8C(S)OR^8$,

(ah) $-NR^8C(S)NR^8R^8$, (ai) $-SC(O)R^8$,

(aj) a C_{1-8} alkyl group, (ak) a C_{2-8} alkenyl group, (al) a C_{2-8} alkynyl group, (am) a C_{1-8} alkoxy group, (an) a C_{1-8} alkylthio group, (ao) a C_{1-8} acyl group, (ap) $-CF_3$,

(aq) $-SCF_3$, (ar) a C_{3-10} saturated, unsaturated, or aromatic carbocycle, and (as) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

alternatively, NR^6R^6 forms a 3-10 membered saturated, unsaturated or aromatic ring including the nitrogen atom to which the R^6 groups are attached wherein said ring is optionally substituted at a position other than the nitrogen atom to which the R^6 groups are bonded, with one or more moieties selected from the group consisting of O, $S(O)_p$, N, and NR^8;

alternatively, CR^6R^6 forms a carbonyl group;

R^7, at each occurrence, is selected from the group consisting of:

(a) H, (b) =O, (c) F, (d) Cl, (e) Br, (f) I, (g) $-CF_3$, (h) –CN, (i) $-N_3$ (j) $-NO_2$, (k) $-NR^6(CR^6R^6)_tR^9$, (l) $-OR^9$, (m) $-S(O)_pC(R^6R^6)_tR^9$, (n) $-C(O)(CR^6R^6)_tR^9$, (o) $-OC(O)(CR^6R^6)_tR^9$, (p) $-SC(O)(CR^6R^6)_tR^9$, (q) $-C(O)O(CR^6R^6)_tR^9$, (r) $-NR^6C(O)(CR^6R^6)_tR^9$, (s) $-C(O)NR^6(CR^6R^6)_tR^9$, (t) $-C(=NR^6)(CR^6R^6)_tR^9$, (u) $-C(=NNR^6R^6)(CR^6R^6)_tR^9$, (v) $-C(=NNR^6C(O)R^6)(CR^6R^6)_tR^9$, (w) $-C(=NOR^9)(CR^6R^6)_tR^9$, (x) $-NR^6C(O)O(CR^6R^6)_tR^9$, (y) $-OC(O)NR^6(CR^6R^6)_tR^9$, (z) $-NR^6C(O)NR^6(CR^6R^6)_tR^9$, (aa) $-NR^6S(O)_p(CR^6R6)_tR^9$, (bb) $-S(O)_pNR^6(CR^6R^6)_tR^9$, (cc) $-NR^6S(O)_pNR^6(CR^6R^6)_tR^9$, (dd) $-NR^6R^6$, (ee) $-NR^6(CR^6R^6)$, (ff) –OH, (gg) $-NR^6R^6$, (hh) $-OCH_3$, (ii) $-S(O)_pR^6$, (jj) $-NC(O)R^6$, (kk) a C_{1-6} alkyl group, (ll) a C_{2-6} alkenyl group, (mm) a C_{2-6} alkynyl group, (nn) $-C_{3-10}$ saturated, unsaturated, or aromatic carbocycle, and (oo) 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of (kk)–(oo) optionally is substituted with one or more R^9 groups;

alternatively, two R^7 groups may form $-O(CH_2)_uO-$;

R^8 is selected from the group consisting of:

(a) R^5,(b) H, (c) a C_{1-6} alkyl group, (d) a C_{2-6} alkenyl group, (e) a C_{2-6} alkynyl group, (f) a C_{3-10} saturated, unsaturated, or aromatic carbocycle, (g) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (h) –C(O)–C_{1-6} alkyl, (i) –C(O)–C_{1-6} alkenyl, (j) –C(O)–C_{1-6} alkynyl, (k) –C(O)–C_{3-10} saturated, unsaturated, or aromatic carbocycle, and (l) –C(O)–3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of (c)–(k) optionally is substituted with one or more moieties selected from the group consisting of : (aa) H, (bb) F, (cc) Cl, (dd) Br, (ee) I, (ff) CN, (gg) NO_2, (hh) OH, (ii) NH_2, (jj) NH(C_{1-6} alkyl), (kk) N(C_{1-6} alkyl)$_2$, (ll) a C_{1-6} alkoxy group, (mm) an aryl group, (nn) a substituted aryl group, (oo) a heteroaryl group, (pp) a substituted heteroaryl group, and qq) a C_{1-6} alkyl group optionally substituted with one or more moieties selected from the group consisting of an aryl group, a substituted aryl group, a heteroaryl group, a substituted heteroaryl group, F, Cl, Br, I, CN, NO_2, CF_3, SCF_3, and OH;

R^9, at each occurrence, independently is selected from the group consisting of:

(a) R^{10}, (b) a C_{1-6} alkyl group, (c) a C_{2-6} alkenyl group, (d) a C_{2-6} alkynyl group, e) a C_{3-10} saturated, unsaturated, or aromatic carbocycle, and f) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of (b)–(f) optionally is substituted with one or more R^{10} groups;

R^{10}, at each occurrence, independently is selected from the group consisting of:

(a) H, (b) =O, (c) F, (d) Cl, (e) Br, (f) I, (g) –CF_3, (h) –CN, (i) –NO_2, (j) –NR^6R^6, (k) –OR^6, (l) –$S(O)_pR^6$, (m) –$C(O)R^6$, (n) –$C(O)OR^6$, (o) –$OC(O)R^6$, (p) $NR^6C(O)R^6$, (q) –$C(O)NR^6R^6$, (r) –$C(=NR^6)R^6$, (s) –$NR^6C(O)NR^6R^6$, (t) –$NR^6S(O)_pR^6$, (u) –$S(O)_pNR^6R^6$, (v) –$NR^6S(O)_pNR^6R^6$, (w) a C_{1-6} alkyl group, (x) a C_{2-6} alkenyl group, (y) a C_{2-6} alkynyl group, (z) a C_{3-10} saturated, unsaturated, or aromatic carbocycle, and (aa) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing

one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of (w)–(aa) optionally is substituted with one or more moieties selected from the group consisting of R^6, F, Cl, Br, I, CN, NO_2, $–OR^6$, $–NH_2$, $–NH(C_{1-6}$ alkyl), $–N(C_{1-6}$ alkyl$)_2$, a C_{1-6} alkoxy group, a C_{1-6} alkylthio group, and a C_{1-6} acyl group;

R^{11} each occurrence, independently is selected from the group consisting of:

(a) a carbonyl group, (b) a formyl group, (c) F, (d) Cl, (e) Br, (f) I, (g) CN, (h) NO_2, (i) OR^8, (j) $–S(O)_pR^8$, (k) $–C(O)R^8$, (l) $–C(O)OR^8$, (m) $–OC(O)R^8$, (n) $–C(O)NR^8R^8$, (o) $–OC(O)NR^8R^8$, (p) $–C(=NR^8)R^8$, (q) $–C(R^8)(R^8)OR^8$, (r) $–C(R^8)_2OC(O)R^8$, (s) $–C(R^8)(OR^8)(CH_2)_rNR^8R^8$, (t) $–NR^8R^8$, (u) $–NR^8OR^8$, (v) $–NR^8C(O)R^8$, (w) $–NR^8C(O)OR^8$, (x) $–NR^8C(O)NR^8R^8$, (y) $–NR^8S(O)_rR^8$, (z) $–C(OR^8)(OR^8)R^8$, (aa) $–C(R^8)_2NR^8R^8$, (bb) $=NR^8$, (cc) $–C(S)NR^8R^8$, (dd) $–NR^8C(S)R^8$, (ee) $–OC(S)NR^8R^8$, (ff) $–NR^8C(S)OR^8$, (gg) $–NR^8C(S)NR^8R^8$, (hh) $–SC(O)R^8$, (ii) a C_{1-8} alkyl group, (jj) a C_{2-8} alkenyl group, (kk) a C_{2-8} alkynyl group, (ll) a C_{1-8} alkoxy group, (mm) a C_{1-8} alkylthio group, (nn) a C_{1-8} acyl group, (oo) a C_{3-10} saturated, unsaturated, or aromatic carbocycle, and (pp) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein (ii)-(kk) optionally are substitued with one or more R^5 groups;

R^{12} is selected from the group consisting of:

(a) H, (b) a C_{1-6} alkyl group, (c) a C_{2-6} alkenyl group, (d) a C_{2-6} alkynyl group, (e) $–C(O)R^5$, (f) $–C(O)OR^5$, (g) $–C(O)–NR^4R^4R^4R^4$, (h) $–C(S)R^5$, (i) $–C(S)OR^5$, (j) $–C(O)SR^5$, (k) $–C(S)-NR^4R^4R^4R^4$, (l) a C_{3-10} saturated, unsaturated, or aromatic carbocycle, or (m) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (n) a $–(C_{1-6}$ alkyl$) –C_{3-10}$ saturated, unsaturated, or aromatic carbocycle, or (o) a $–(C_{1-6}$ alkyl)-3-10 membered saturated, unsaturated, or aromatic

heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein (a)–(d) and (l)–(o) optionally are substitued with one or more R^5 groups;

p at each occurrence is 0, 1, or 2;

r at each occurrence is 0, 1, or 2;

t at each occurrence is 0, 1, or 2;

u at each occurrence is 1, 2, 3, or 4;

provided that

i) when T is a 14 or 15 membered macrolide D–E is not



ii) when T is a 14 or 15 membered macrolide F–B' is not



iii) when T is a 14 or 15 membered macrolide B'–Z–B" is not



iv) when T is a 14 or 15 membered macrolide R^{11} is not



, or , ,

v) when the compound has formula I and T is



D is not a single bond or a $-CH_2-$,

vi) when the compound has formula I and T is a 14 or 15 membered macrolide –D–E–F– is not a $-CH_2-$,

vii) when the compound has formula I and T is a 14 or 15 membered macrolide –D–E–F–G– is not a chemical moiety selected from the chemical moieties listed in Table A

Table A

			
			
			

, and

viii) when the compound has formula II and T is a 16 membered macrolide

i. -D-E- is not a glycoside attached via its anomeric carbon,

ii. -D-E-F-G is not a C_{1-4} (alkyl), C_{2-4}(alkenyl), or C_{2-4}(alkynyl) chain bonded to a 5-10 membered monocyclic or bicyclic carbocyle or heterocycle or bonded to a 5 or 6 membered carbocycle or heterocycle further bonded to a 5 or 6 membered carbocycle or heterocycle, any of said carbocycles or heterocycles being optionally substituted with one or more groups selected from the group consisting of (aa) –OH, (bb) –F, (cc) –Cl, (dd) –I, and (ee) – NO_2, and

iii. -D-E-F-G- is not a chemical moiety selected from the chemical moieties listed in Table B.

Table B

	-(t-butoxycarboxy)-3-(3-quinolyl)

.

2. (Original) A compound according to claim 1, having the formula:



I

or



II

,

or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein T, D, E, F, G, R^1, R^2 and R^3 are as described in claim 1.

3. (Currently amended) A compound according to claim ~~1 or~~ 2 having the formula:



I

or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein T, D, E, F, G, R^1, R^2 and R^3 are as described in claim 1.

4. (Currently amended) A compound according to claim ~~1 or~~ 2 having the formula:



II

or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein T, D, E, F, G, R^1, R^2 and R^3 are as described in claim 1.

5. (Currently amended) A compound according to ~~any one of claims 1-4~~claim 1, or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein T is a 14- or 15-membered macrolide connected via a macrocyclic ring carbon atom.

6. (Currently amended) A compound according to ~~any one of claims 1-5~~claim 1, or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein G is B′.

7. (Currently amended) A compound according to claim 6 or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein B′ is selected from the group consisting of: (a) an aryl group, (b) a heteroaryl group, (c) a biaryl group, and (d) a fused bicyclic or tricyclic unsaturated or aromatic ring system optionally containing one or more carbonyl groups and one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein each (a)-(d) optionally is substituted with one or more R^{11} groups.

8. (Currently amended) A compound according to claim 6, or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein E is

(a) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

(b) a 3-10 membered saturated, unsaturated, or aromatic carbocycle,

(c) a –W–[3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur],

(d) a –W–[3-10 membered saturated, unsaturated, or aromatic carbocycle],

(e) –C(O)–, (f) –C(O)O–, (g) –C(O)NR^4–, (h) –C(=NR^4)–,

(i) –C(=NR^4)O-, (j) –C(=NR^4)NR^4–, (k) –OC(O)–, (l) –OC(O)O–,

(m) –OC(O)NR^4–, (n) –NR^4C(O)–, (o) –NR^4C(O)O–,

(p) –NR^4C(O)NR^4–, (q) –NR^4C(=NR^4)NR^4–, (r) –$S(O)_p$–,

(s) –$NR^4S(O)_2$–, (t) –$S(O)_2NR^4$–, (u) –C(N–OR^4)–, (v) –C(N-NR^4R^4)–,

(w) –C(S)NR^4–, (x) – NR^4C(S) –, (y) –C(S)O–, or (z) –OC(S) –, wherein

i) any of (a)-(d) immediately above optionally is substituted with one or more R^5 groups; and

ii) W is selected from the group consisting of:

(aa) –OCO–, (bb) –OC(O)O–, (cc) –OC(O)NR^4–, (dd) –NR^4C(O)O–,

(ee) –OCNOR^4–, (ff) –NR^4–C(O)O–, (gg) –C(S)(NR^4)–, (hh) –NR^4–,

(ii) –OC(S)O–, (jj) –OC(S)NR^4–, (kk) –NR^4C(S)O–, (ll) –OC(S)NOR^4–, (mm) –C(S)O–, (nn) –OC(S)–, (oo) –C(O)–, (pp) –

C(O)O–, (qq) –C(O)NR^4–, (rr) –C(=NR^4)–, (ss) –C(=NR^4)O–, (tt) – C(=NR^4)NR^4–, (uu) –OC(O)–, (vv) –OC(O)O–, (ww) –OC(O)NR^4–, (xx) –NR^{4}C(O)–, (yy) –NR^{4}C(O)O–, (zz) –NR^{4}C(O)NR^4–, (aaa) – NR^{4}C(=NR^4)NR^4–, (bbb) –S(O)$_p$–, (ccc) –NR^{4}S(O)$_2$–, (ddd) – S(O)$_2$NR^4–, (eee) –C(N–OR^4)–, (fff) –C(N-NR^{4}R^4)–, (ggg) – C(S)NR^4–, or (hhh) –NR^{4}C(S)–.

9. (Currently amended) A compound according to ~~any one of claims 1–8~~claim 1~~,~~ or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein

D is selected from the group consisting of (a) a C_{1-6} alkyl group, (b) a C_{2-6} alkenyl group, and (c) a C_{2-6} alkynyl group, wherein

i) 0-2 carbon atoms in any of (a)–(c) of D immediately above optionally is replaced by a moiety selected from the group consisting of O, S(O)$_p$, and NR^4,

ii) any of (a)–(c) of D immediately above optionally is substituted with one or more R^5 groups; and

F is selected from the group consisting of (a) a single bond, (b) a C_{1-6} alkyl group, (c) a C_{2-6} alkenyl group, and (d) a C_{2-6} alkynyl group, wherein

i) 0-2 carbon atoms in any of (b)–(d) of F immediately above optionally is replaced by a moiety selected from the group consisting of O, S(O)$_p$, and NR^4;

ii) any of (b)–(d) of F immediately above optionally is substituted with one or more R^5 groups; and

iii) any of (b)–(d) of F immediately above optionally is substituted with C_{1-6} alkyl-R^5.

10. (Currently amended) A compound according to claim 9~~,~~ or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein

E is selected from the group consisting of:

(a) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

(b) a 3-10 membered saturated, unsaturated, or aromatic carbocycle,

(c) a –W–[3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur],

(d) a –W–[3-10 membered saturated, unsaturated, or aromatic carbocycle],

(e) –C(O)–, (f) –C(O)O–, (g) –C(O)NR^4–, (h) –C(=NR^4)–, (i) –C(=NR^4)O-, (j) –C(=NR^4)NR^4–, (k) –OC(O)–, (l) –OC(O)O–,

(m) –OC(O)NR^4–, (n) –NR^4C(O)–, (o) –NR^4C(O)O–, (p) –NR^4C(O)NR^4–, (q) –NR^4C(=NR^4)NR^4–, (r) –$S(O)_p$–, (s) –$NR^4S(O)_2$–, (t) –$S(O)_2NR^4$–, (u) –C(N–OR^4)–, (v) –CH_2–, (w) –C(N-NR^4R^4)–, (x) –C(S)NR^4, (Y) –NR^4C(S)–, (Z) –C(S)O–, or (aa) –OC(S)–, wherein

i) any of (a)-(d) immediately above optionally is substituted with one or more R^5 groups; and

ii) W is selected from the group consisting of:

(aa) –OCO–, (bb) –OC(O)O–, (cc) –OC(O)NR^4–,

(dd) –NR^4C(O)O–, (ee) –OCNOR^4–,

(ff) –NR^4–C(O)O–, (gg) –C(S)(NR^4)–, (hh) –NR^4,

(ii) –OC(S)O–, (jj) –OC(S)NR^4–, (kk) –NR^4C(S)O–, (ll) –OC(S)NOR^4–, (mm) –C(S)O–, (nn)-OC(S), (oo) –C(O)–, (pp) –C(O)O–, (qq) –C(O)NR^4–, (rr) –C(=NR^4)–,

(ss) –C(=NR^4)O-, (tt) –C(=NR^4)NR^4–, (uu) –OC(O)–, (vv) –OC(O)O–, (ww) –OC(O)NR^4–, (xx) –NR^4C(O)–, (yy) –NR^4C(O)O–, (zz) –NR^4C(O)NR^4–, (aaa) –NR^4C(=NR^4)NR^4–, (bbb) –$S(O)_p$–, (ccc) –$NR^4S(O)_2$–, (ddd) –$S(O)_2NR^4$–, (eee) –C(N–OR^4)–, (fff) –C(N-NR^4R^4)–, (ggg) –C(S)NR^4–, or (hhh)-NR^4C(S)–.

11. (Currently amended) A compound according to claim 10, or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein

E is selected from the group consisting of:

(a) a 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and

(b) a 3-10 membered saturated, unsaturated, or aromatic carbocycle,

wherein (a) and (b) immediately above optionally is substituted with one more R^5 groups.

12. (Currently amended) A compound according to claim 9, or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof wherein

E is selected from the group consisting of:

(a) $-C(O)-$, (b) $-C(O)O-$, (c) $-C(O)NR^4-$, (d) $-C(=NR^4)-$,
(e) $-C(=NR^4)O-$, (f) $-C(=NR^4)NR^4-$, (g) $-OC(O)-$, (h) $-OC(O)O-$, (i) $-OC(O)NR^4-$,
(j) $-NR^4C(O)-$, (k) $-NR^4C(O)O-$, (l) $-NR^4C(O)NR^4-$, (m) $-NR^4C(=NR^4)NR^4-$, (n) $-S(O)_p-$, (o) $-NR^4S(O)_2-$, (p) $-S(O)_2NR^4-$, (q) $-C(N\text{-}OR^4)-$, (r) $-CH_2-$, (s) $-C(N-NR^4R^4)-$, (t), $-C(S)NR^4$, (u) $-NR^4C(S)-$, (v) -C(S)O, and (w) $-OC(S)-$.

13. (Currently amended) A compound according to any one of according to ~~any one of claims 1-12~~claim 1, wherein T is:



,

or an *N*-oxide, pharmaceutically acceptable salt, ester or prodrug thereof,

wherein:

M is selected from the group consisting of:

(a) –C((O)–, (b) –CH(–OR^{114})–, (c) –NR^{114}–CH_2–, (d) –CH_2–NR^{114}–, (e) –CH($NR^{114}R^{114}$)–, (f) –C(=N$NR^{114}R^{114}$)–, (g) –NR^{114}–C(O)–, (h) –C(O)NR^{114}–, (i) –C(=NR^{114})–, and (j) –$CR^{115}R^{115}$–, (k) –C(=NOR^{127})–;

R^{100} is selected from the group consisting of H and C_{1-6} alkyl;

R^{101} is selected from the group consisting of:

(a) H, (b) Cl, (c) F, (d) Br, (e) I, (f) –$NR^{114}R^{114}$, (g) –NR^{114}C(O)R^{114}, (h) –OR^{114}, (i) –OC(O)R^{114}, (j) –OC(O)OR^{114}, (k) –OC(O)$NR^{114}R^{114}$, (l) –O–C_{1-6} alkyl, (m) –OC(O)–C_{1-6} alkyl, (n) –OC(O)O–C_{1-6} alkyl, (o) –OC(O)NR^{114}–C_{1-6} alkyl, (p) C_{1-6} alkyl, (q) C_{1-6} alkenyl, (r) C_{1-6} alkynyl,

wherein any of (l) – (r) optionally is substituted with one or more R^{115} groups;

R^{102} is H;

R^{103} is selected from the group consisting of:

(a) H, (b) –OR^{114}, (c) –O–C_{1-6} alkyl–R^{115}, (d) –OC((O)R^{114}, (e) –OC(O)–C_{1-6} alkyl–R^{115}, (f) –OC(O)OR^{114}, (g) –OC(O)O–C_{1-6} alkyl–R^{115}, (h) –OC(O)$NR^{114}R^{114}$, (i) –OC(O)NR^{114}–C_{1-6} alkyl–R^{115}, and (j)



;

alternatively, R^{102} and R^{103} taken together form a carbonyl group;

alternatively, R^{101} and R^{103} taken together are a single bond between the respective carbons to which these two groups are attached thereby creating a double bond between the carbons to which R^{100} and R^{102} are attached;

alternatively, R^{101} and R^{103} taken together are an epoxide moiety.

R^{104} is selected from the group consisting of:

(a) H, (b) R^{114}, (c) $-C(O)R^{114}$(d) $-C(O)OR^{114}$ (e) $-C(O)NR^{114}R^{114}$, (f) $-C_{1\text{-}6}$ alkyl–K–R^{114}, (g) $-C_{2\text{-}6}$ alkenyl–K–R^{114}, and (h) $-C_{2\text{-}6}$ alkynyl–K–R^{114};

alternatively R^{103} and R^{104}, taken together with the atoms to which they are bonded, form:



;

K is selected from the group consisting of:

(a) –C(O)–, (b) –C(O)O–, (c) $-C(O)NR^{114}$–, (d) $-C(=NR^{114})$–, (e) $-C(=NR^{114})O$–, (f) $-C(=NR^{114})NR^{114}$–, (g) –OC(O)–, (h) –OC(O)O–, (i) $-OC(O)NR^{114}$–, (j) $-NR^{114}C(O)$–, (k) $-NR^{114}C(O)O$–, (l) $-NR^{114}C(O)NR^{114}$–, (m) $-NR^{114}C(=NR^{114})NR^{114}$–, and (o) $-S(O)_p$–;

R^{105} is selected from the group consisting of:

(a) R^{114}, (b) $-OR^{114}$, (c) $-NR^{114}R^{114}$, (d) $-O-C_{1\text{-}6}$ alkyl–R^{115}, (e) $-C(O)-R^{114}$, (f) $-C(O)-C_{1\text{-}6}$ alkyl–R^{115}, (g) $-OC(O)-R^{114}$, (h) $-OC(O)-C_{1\text{-}6}$ alkyl–R^{115}, (i) $-OC(O)O-R^{114}$, (j) $-OC(O)O-C_{1\text{-}6}$ alkyl–R^{115}, (k) $-OC(O)NR^{114}R^{114}$, (l) $-OC(O)NR^{114}-C_{1\text{-}6}$ alkyl–R^{115}, (m) $-C(O)-C_{2\text{-}6}$ alkenyl–R^{115}, and (n) $-C(O)-C_{2\text{-}6}$ alkynyl–R^{115};

alternatively, R^{104} and R^{105}, taken together with the atoms to which they are bonded, form:



,

wherein

Q is CH or N, and R^{126} is $-OR^{114}$, $-NR^{114}$ or R^{114};

alternatively, R^{104} and R^{105}, taken together with the atoms to which they are bonded, form:



,

wherein

i) R^{101} is as defined above;

ii) alternately, R^{101} and R^{109} may be taken together form a carbonyl group;

iii) alternately, R^{101} and R^{109} may be taken together to form the group –$O(CR^{116}R^{116})_uO$–;

alternatively, R^{104} and R^{105}, taken together with the atoms to which they are bonded, form:



i) R^{130} is –OH, =C(O), or R^{114},

ii) R^{131} is –OH, =C(O), or R^{114},

iii) alternately, R^{130} and R^{131} together with the carbons to which they are attached form a 3-7 membered saturated, unsaturated or aromatic carbocyclic or heterocyclic ring which can optionally be substituted with one or more R^{114} groups;

R^{106} is selected from the group consisting of:

(a) –OR^{114}, (b) –$C_{1\text{-}6}$ alkoxy–R^{115}, (c) –$C(O)R^{114}$, (d) –$OC(O)R^{114}$, (e) –$OC(O)OR^{114}$, (f) –$OC(O)NR^{114}R^{114}$, and (g) –$NR^{114}R^{114}$,

alternatively, R^{105} and R^{106} taken together with the atoms to which they are attached form a 5-membered ring by attachment to each other through a chemical moiety selected from the group consisting of:

(a) –$OC(R^{115})_2O$–, (b) –OC(O)O–, (c) –$OC(O)NR^{114}$–, (d) –$NR^{114}C(O)O$–, (e) –$OC(O)NOR^{114}$–, (f) –NOR^{114}–C(O)O–, (g) –$OC(O)NNR^{114}R^{114}$–, (h) –$NNR^{114}R^{114}$–C(O)O–, (i) –$OC(O)C(R^{115})_2$–, (j) –$C(R^{115})_2C(O)O$–, (k) –OC(S)O–, (l) –$OC((S)NR^{114}$–, (m) –$NR^{114}C(S)O$–, (n) –$OC(S)NOR^{114}$–, (o) –NOR^{114}–C(S)O–, (p) –$OC(S)NNR^{114}R^{114}$–, (q) –$NNR^{114}R^{114}$–C(S)O–, (r) –$OC(S)C(R^{115})_2$–, and (s) –$C(R^{115})_2C(S)O$–;

alternatively, M, R^{105}, and R^{106} taken together with the atoms to which they are attached form:









wherein J is selected from the group consisting of O, S and NR^{114};

alternatively, M and R^{104} taken together with the atoms to which they are attached form:



96



97

98



99

100

101 R^{107} is selected from the group consisting of

102 (a) H, (b) $-C_{1-4}$ alkyl, (c) $-C_{2-4}$ alkenyl, which can be further substituted with C_{1-12}

103 alkyl or one or more halogens, (d) $-C_{2-4}$ alkynyl, which can be further substituted

104 with C_{1-12} alkyl or one or more halogens, (e) aryl or heteroaryl, which can be further

105 substituted with C_{1-12} alkyl or one or more halogens, (f) –C(O)H, (g) –COOH, (h) –

106 CN, (i) $-COOR^{114}$, (j) $-C(O)NR^{114}R^{114}$, (k) $-C(O)R^{114}$, and (l) $-C(O)SR^{114}$, wherein

107 (b) is further substituted with one or more substituents selected from the group

108 consisting of (aa) $-OR^{114}$, (bb) halogen, (cc) $-SR^{114}$, (dd) C_{1-12} alkyl, which can be

109 further substituted with halogen, hydroxyl, C_{1-6} alkoxy, or amino, (ee) $-OR^{114}$, (ff) –

110 SR^{114}, (gg) $-NR^{114}R^{114}$, (hh) –CN, (ii)-NO_2, (jj) $-NC(O)R^{114}$, (kk) $-COOR^{114}$, (ll) –

111 N_3, (mm) $=N\text{-}O\text{-}R^{114}$, (nn) $=NR^{114}$, (oo) $=N\text{-}NR^{114}R^{114}$, (pp) $=N\text{-}NH\text{-}C(O)R^{114}$, and

112 (qq) $=N\text{-}NH\text{-}C(O)NR^{114}R^{114}$;

113 alternatively R^{106} and R^{107} are taken together with the atom to which they are attached to

114 form an epoxide, a carbonyl, an olefin, or a substituted olefin, or a C_3-C_7 carbocyclic, carbonate, or

115 carbamate, wherein the nitrogen of said carbamate can be further substituted with a C_1-C_6 alkyl;

116 R^{108} is selected from the group consisting of:

117 (a) C_{1-6} alkyl, (b) C_{2-6} alkenyl, and (c) C_{2-6} alkynyl,

118 wherein any of (a)–(c) optionally is substituted with one or more R^{114} groups;

119 R^{111} is selected from the group consisting of H and $-C(O)R^{114}$;

120 R^{112} is selected from the group consisting of H, OH, and OR^{114};

121 R^{113} is selected from the group consisting of:

(a) H, (b) R^{114}, (c) $-C_{1-6}$ alkyl–K–R^{114}, (d) $-C_{2-6}$ alkenyl–K–R^{114}, and
(e) $-C_{2-6}$ alkynyl–K–R^{114},
wherein any of (c)-(e) optionally is substituted with one or more R^{115} groups;
R^{114}, at each occurrence, independently is selected from the group consisting of:
(a) H, (b) C_{1-6} alkyl, (c) C_{2-6} alkenyl, (d) C_{2-6} alkynyl, (e) C_{6-10} saturated, unsaturated, or aromatic carbocycle, (f) 3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (g) $-C(O)-C_{1-6}$ alkyl, (h) $-C(O)-C_{2-6}$ alkenyl, (i) $-C(O)-C_{2-6}$ alkynyl, (j) $-C(O)-C_{6-10}$ saturated, unsaturated, or aromatic carbocycle, (k) –C(O)–3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (l) $-C(O)O-C_{1-6}$ alkyl, (m) $-C(O)O-C_{2-6}$ alkenyl, (n) $-C(O)O-C_{2-6}$ alkynyl, (o) $-C(O)O-C_{6-10}$ saturated, unsaturated, or aromatic carbocycle, (p) –C(O)O–3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (q) $-C(O)NR^{116}R^{116}$,
wherein any of (b)–(p) optionally is substituted with one or more R^{115} groups,
wherein one or more non-terminal carbon moieties of any of (b)–(d) optionally is replaced with oxygen, $S(O)_p$, or $-NR^{116}$,
alternatively, $NR^{114}R^{114}$ forms a 3-7 membered saturated, unsaturated or aromatic ring including the nitrogen atom to which the R^{114} groups are bonded and optionally one or more moieties selected from the group consisting of O, $S(O)_p$, N, and NR^{118};
R^{115} is selected from the group consisting of:
(a) R^{117}, (b) C_{1-8} alkyl, (c) C_{2-8} alkenyl, (d) C_{2-8} alkynyl, (e) C_{3-12} saturated, unsaturated, or aromatic carbocycle, (f) 3-12 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of (b)–(f) optionally is substituted with one or more R^{117} groups;
R^{116}, at each occurrence, independently is selected from the group consisting of:

(a) H, (b) C_{1-6} alkyl, (c) C_{2-6} alkenyl, (d) C_{2-6} alkynyl, (e) C_{3-10} saturated, unsaturated, or aromatic carbocycle, and (f) 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein one or more non-terminal carbon moieties of any of (b)–(d) optionally is replaced with oxygen, $S(O)_p$, or $-NR^{114}$, wherein any of (b)– (f) optionally is substituted with one or more moieties selected from the group consisting of:

(aa) carbonyl, (bb) formyl, (cc) F, (dd) Cl, (ee) Br, (ff) I, (gg) CN, (hh) N_3, (ii)NO_2, (jj) OR^{118}, (kk) $-S(O)_pR^{118}$, (ll) $-C(O)R^{118}$, (mm) $-C(O)OR^{118}$, (nn) $-OC(O)R^{118}$, (oo) $-C(O)NR^{118}R^{118}$, (pp) $-OC(O)NR^{118}R^{118}$, (qq) $-C(=NR^{118})R^{118}$, (rr) $-C(R^{118})(R^{118})OR^{118}$, (ss) $-C(R^{118})_2OC(O)R^{118}$, (tt) $-C(R^{118})(OR^{118})(CH_2)_rNR^{118}R^{118}$, (uu) $-NR^{118}R^{118}$; (vv) $-NR^{118}OR^{118}$, (ww) $-NR^{118}C(O)R^{118}$, (xx) $-NR^{118}C(O)OR^{118}$, (yy) $-NR^{118}C(O)NR^{118}R^{118}$, (zz) $-NR^{118}S(O)_rR^{118}$, (ab) $-C(OR^{118})(OR^{118})R^{118}$, (ac) $-C(R^{118})_2NR^{118}R^{118}$, (ad) $=NR^{118}$, (ae) $-C(S)NR^{118}R^{118}$, (af) $-NR^{118}C(S)R^{118}$, (ag) $-OC(S)NR^{118}R^{118}$, (ah) $-NR^{118}C(S)OR^{118}$, (ai) $-NR^{118}C(S)NR^{118}R^{118}$, (aj) $-SC(O)R^{118}$, (ak) C_{1-8} alkyl, (al) C_{2-8} alkenyl, (am) C_{2-8} alkynyl, (an) C_{1-8} alkoxy, (ao) C_{1-8} alkylthio, (ap) C_{1-8} acyl, (aq) saturated, unsaturated, or aromatic C_{3-10} carbocycle, and (ar) saturated, unsaturated, or aromatic 3-10 membered heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

alternatively, $NR^{116}R^{116}$ forms a 3-10 membered saturated, unsaturated or aromatic ring including the nitrogen atom to which the R^{116} groups are attached and optionally one or more moieties selected from the group consisting of O, $S(O)_p$, N, and NR^{118};

alternatively, $CR^{116}R^{116}$ forms a carbonyl group;

R^{117}, at each occurrence, is selected from the group consisting of:

(a) H, (b) =O, (c) F, (d) Cl, (e) Br, (f) I, (g) $(CR^{116}R^{116})_rCF_3$, (h) $(CR^{116}R^{116})_rCN$, (i) $(CR^{116}R^{116})_rNO2$, (j) $(CR^{116}R^{116})_rNR^{116}(CR^{116}R^{116})_tR^{119}$, (k) $(CR^{116}R^{116})_rOR^{119}$,

(l) $(CR^{116}R^{116})_rS(O)_p(CR^{116}R^{116})_tR^{119}$, (m) $(CR^{116}R^{116})_rC(O)(CR^{116}R^{116})_tR^{119}$, (n) $(CR^{116}R^{116})_rOC(O)(CR^{116}R^{116})_tR^{119}$, (o) $(CR^{116}R^{116})_rSC(O)(CR^{116}R^{116})_tR^{119}$, (p) $(CR^{116}R^{116})_rC(O)O(CR^{116}R^{116})_tR^{119}$, (q) $(CR^{116}R^{116})_rNR^{116}C(O)(CR^{116}R^{116})_tR^{119}$, (r) $(CR^{116}R^{116})_rC(O)NR^{116}(CR^{116}R^{116})_tR^{119}$, (s) $(CR^{116}R^{116})_rC(=NR^{116})(CR^{116}R^{116})_tR^{119}$, (t) $(CR^{116}R^{116})_rC(=NNR^{116}R^{116})(CR^{116}R^{116})_tR^{119}$, (u) $(CR^{116}R^{116})_rC(=NNR^{116}C(O)R^{116})(CR^{116}R^{116})_tR^{119}$, (v) $(CR^{116}R^{116})_rC(=NOR^{119})(CR^{116}R^{116})_tR^{119}$, (w) $(CR^{116}R^{116})_rNR^{116}C(O)O(CR^{116}R^{116})_tR^{119}$, (x) $(CR^{116}R^{116})_rOC(O)NR^{116}(CR^{116}R^{116})_tR^{119}$, (y) $(CR^{116}R^{116})_rNR^{116}C(O)NR^{116}(CR^{116}R^{116})_tR^{119}$, (z) $(CR^{116}R^{116})_rNR^{116}S(O)_p(CR^{116}R^{116})_tR^{119}$, (aa) $(CR^{116}R^{116})_rS(O)_pNR^{116}(CR^{116}R^{116})_tR^{119}$, (bb) $(CR^{116}R^{116})_rNR^{116}S(O)_pNR^{116}(CR^{116}R^{116})_tR^{119}$, (cc) $(CR^{116}R^{116})_rNR^{116}R^{116}$, (dd) $C_{1\text{-}6}$ alkyl, (ee) $C_{2\text{-}6}$ alkenyl, (ff) $C_{2\text{-}6}$ alkynyl, (gg) $(CR^{116}R^{116})_r$–$C_{3\text{-}10}$ saturated, unsaturated, or aromatic carbocycle, and (hh) $(CR^{116}R^{116})_r$–3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of (dd)–(hh) optionally is substituted with one or more R^{119} groups;

alternatively, two R^{117} groups may form $–O(CH_2)_uO–$;

R^{118} is selected from the group consisting of:

(a) H, (b) $C_{1\text{-}6}$ alkyl, (c) $C_{2\text{-}6}$ alkenyl, (d) $C_{2\text{-}6}$ alkynyl, (e) $C_{3\text{-}10}$ saturated, unsaturated, or aromatic carbocycle, (f) 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (g) $–C(O)–C_{1\text{-}6}$ alkyl, (h) $–C(O)–C_{1\text{-}6}$ alkenyl, (g) $–C(O)–C_{1\text{-}6}$ alkynyl, (i) $–C(O)–C_{3\text{-}10}$ saturated, unsaturated, or aromatic carbocycle, and (j) –C(O)–3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of (b)–(j) optionally is substituted with one or more moieties selected from the group consisting of : (aa) H, (bb) F, (cc) Cl, (dd) Br, (ee) I,

(ff) CN, (gg) NO_2, (hh) OH, (ii) NH_2, (jj) $NH(C_{1-6}$ alky(l), (kk) $N(C_{1-6}$ alky(l)$_2$, (ll) C_{1-6} alkoxy, (mm) aryl, (nn) substituted aryl, (oo) heteroaryl, (pp) substituted heteroaryl, and (qq) C_{1-6} alkyl, optionally substituted with one or more moieties selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, F, Cl, Br, I, CN, NO_2, and OH;

R^{119}, at each occurrence, independently is selected from the group consisting of:

(a) R^{120}, (b) C_{1-6} alkyl, (c) C_{2-6} alkenyl, (d) C_{2-6} alkynyl, (e) C_{3-10} saturated, unsaturated, or aromatic carbocycle, and (f) 3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of (b)–(f) optionally is substituted with one or more R^{119} groups;

R^{120}, at each occurrence, independently is selected from the group consisting of:

(a) H, (b) =O, (c) F, (d) Cl, (e) Br, (f) I, (g) $(CR^{116}R^{116})_rCF_3$, (h) $(CR^{116}R^{116})_rCN$, (i) $(CR^{116}R^{116})_rNO_2$, (j) $(CR^{116}R^{116})_rNR^{116}R^{116}$, (k) $(CR^{116}R^{116})_rOR^{114}$, (l) $(CR^{116}R^{116})_rS(O)_pR^{116}$, (m) $(CR^{116}R^{116})_rC(O)R^{116}$, (n) $(CR^{116}R^{116})_rC(O)OR^{116}$, (o) $(CR^{116}R^{116})_rOC(O)R^{116}$, (p) $(CR^{116}R^{116})_rNR^{116}C(O)R^{116}$, (q) $(CR^{116}R^{116})_rC(O)NR^{116}R^{116}$, (r) $(CR^{116}R^{116})_rC(=NR^{116})R^{116}$, (s) $(CR^{116}R^{116})_rNR^{116}C(O)NR^{116}R^{116}$, (t) $(CR^{116}R^{116})_rNR^{116}S(O)_pR^{116}$, (u) $(CR^{116}R^{116})_rS(O)_pNR^{116}R^{116}$, (v) $(CR^{116}R^{116})_rNR^{116}S(O)_pNR^{116}R^{116}$, (w) C_{1-6} alkyl, (x) C_{2-6} alkenyl, (y) C_{2-6} alkynyl, (z) $(CR^{116}R^{116})_r$–C_{3-10} saturated, unsaturated, or aromatic carbocycle, and (aa) $(CR^{116}R^{116})_r$–3-10 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of (w)–(aa) optionally is substituted with one or more moieties selected from the group consisting of R^{116}, F, Cl, Br, I, CN, NO_2, $–OR^{116}$, $–NH_2$, $–NH(C_{1-6}$ alkyl), $–N(C_{1-6}$ alkyl)$_2$, C_{1-6} alkoxy, C_{1-6} alkylthio, and C_{1-6} acyl;

R^{121}, at each occurrence, independently is selected from the group consisting of:

(a) H, (b) $-OR^{118}$, (c) $-O-C_{1-6}$ alkyl$-OC(O)R^{118}$, (d) $-O-C_{1-6}$ alkyl$-OC(O)OR^{118}$, (e) $-O-C_{1-6}$ alkyl$-OC(O)NR^{118}R^{118}$, (f) $-O-C_{1-6}$ alkyl$-C(O)NR^{118}R^{118}$, (g) $-O-C_{1-6}$ alkyl$-NR^{118}C(O)R^{118}$, (h) $-O-C_{1-6}$ alkyl$-NR^{118}C(O)OR^{118}$, (i) $-O-C_{1-6}$ alkyl$-NR^{118}C(O)NR^{118}R^{118}$, (j) $-O-C_{1-6}$ alkyl$-NR^{118}C(=N(H)NR^{118}R^{118}$, (k) $-O-C_{1-6}$ alkyl$-S(O)_pR^{118}$, (l) $-O-C_{2-6}$ alkenyl$-OC(O)R^{118}$, (m) $-O-C_{2-6}$ alkenyl$-OC(O)OR^{118}$, (n) $-O-C_{2-6}$ alkenyl$-OC(O)NR^{118}R^{118}$, (o) $-O-C_{2-6}$ alkenyl$-C(O)NR^{118}R^{118}$, (p) $-O-C_{2-6}$ alkenyl$-NR^{118}C(O)R^{118}$, (q) $-O-C_{2-6}$ alkenyl$-NR^{118}C(O)OR^{118}$, (r) $-O-C_{2-6}$ alkenyl$-NR^{118}C(O)NR^{118}R^{118}$, (s) $-O-C_{2-6}$ alkenyl$-NR^{118}C(=N(H)NR^{118}R^{118}$, (t) $-O-C_{2-6}$ alkenyl$-S(O)_pR^{118}$,

(u) $-O-C_{2-6}$ alkynyl$-OC(O)R^{118}$, (v) $-O-C_{2-6}$ alkynyl$-OC(O)OR^{118}$, (w) $-O-C_{2-6}$ alkynyl$-OC(O)NR^{118}R^{118}$, (x) $-O-C_{2-6}$ alkynyl$-C(O)NR^{118}R^{118}$, (y) $-O-C_{2-6}$ alkynyl$-NR^{118}C(O)R^{118}$, (z) $-O-C_{2-6}$ alkynyl$-NR^{118}C(O)OR^{118}$, (aa) $-O-C_{2-6}$ alkynyl$-NR^{118}C(O)NR^{118}R^{118}$,

(bb) $-O-C_{2-6}$ alkynyl$-NR^{118}C(=N(H)NR^{118}R^{118}$, (cc) $-O-C_{2-6}$ alkynyl$-S(O)_pR^{118}$; and

(dd) $-NR^{118}R^{118}$;

alternatively, two R^{121} groups taken together form =O, $=NOR^{118}$, or $=NNR^{118}R^{118}$;

R^{122} is R^{115};

R^{123} is selected from the group consisting of:

(a) R^{116}, (b) F, (c) Cl, (d) Br, (e) I, (f) CN, (g) NO_2, and (h) $-OR^{114}$;

alternatively, R^{122} and R^{123} taken together are $-O(CH_2)_uO-$;

R^{124}, at each occurrence, independently is selected from the group consisting of:

(a) H, (b) F, (c) Cl, (d) Br, (e) I, (f) CN, (g) $-OR^{114}$, (h) $-NO_2$, (i) $-NR^{114}R^{114}$, (j) C_{1-6} alkyl, (k) C_{1-6} acyl, and (l) C_{1-6} alkoxy;

R^{125} is selected from the group consisting of:

(a) C_{1-6} alkyl, (b) C_{2-6} alkenyl, (c) C_{2-6} alkynyl, (d) C_{1-6} acyl, (e) C_{1-6} alkoxy, (f) C_{1-6} alkylthio, (g) saturated, unsaturated, or aromatic C_{5-10} carbocycle, (h) saturated, unsaturated, or aromatic 5-10 membered heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (i) $-O-C_{1-6}$ alkyl-saturated, unsaturated, or aromatic 5-10 membered heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen,

oxygen, and sulfur, (j) $-NR^{114}$-C_{1-6} alkyl-saturated, unsaturated, or aromatic 5-10 membered heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (k) saturated, unsaturated, or aromatic 10-membered bicyclic ring system optionally containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (l) saturated, unsaturated, or aromatic 13-membered tricyclic ring system optionally containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (m) $-OR^{114}$,

(n) $-NR^{114}R^{114}$, (o) $-S(O)_pR^{114}$, and (p) $-R^{124}$,

wherein any of (a)-(l) optionally is substituted with one or more R^{115} groups;

alternatively, R^{125} and one R^{124} group, taken together with the atoms to which they are bonded, form a 5-7 membered saturated or unsaturated carbocycle, optionally substituted with one or more R^{115} groups; or a 5-7 membered saturated or unsaturated heterocycle containing one or more atoms selected from the group consisting of nitrogen, oxygen, and sulfur, and optionally substituted with one or more R^{115} groups;

R^{126} at each occurrence, independently is selected from the group consisting of:

(a) hydrogen, (b) an electron-withdrawing group, (c) aryl, (d) substituted aryl, (e) heteroaryl, (f) substituted heteroaryl, and (g) C_{1-6} alkyl, optionally substituted with one or more R^{115} groups;

alternatively, any R^{126} and any R^{123}, taken together with the atoms to which they are bonded, form a 5-7 membered saturated or unsaturated carbocycle, optionally substituted with one or more R^{115} groups; or a 5-7 membered saturated or unsaturated heterocycle containing one or more atoms selected from the group consisting of nitrogen, oxygen, and sulfur, and optionally substituted with one or more R^{115} groups;

R^{109} is H or F;

R^{127} is R^{114}, a monosaccharide or disaccharide (including amino sugars and halo sugar(s), $-(CH_2)_n$-$(O$-CH_2CH_2-$)_m$-$O(CH_2)_pCH_3$ or $-(CH_2)_n$-$(O$-CH_2CH_2-$)_m$-OH

R^{128} is R^{114}

R^{129} is R^{114}

R^{110} is R^{114}

Alternatively, R^{109} and R^{110} taken together with the carbons to which they are attached form:



Alternately, R^{128} and R^{129} together with the carbons to which they are attached form a 3-6 membered saturated, unsaturated or aromatic carbocyclic or heterocyclic ring which may optionally be substituted with one or more R^{114} groups;

m, at each occurrence is 0, 1, 2, 3, 4, or 5;

n, at each occurrence is 1, 2, or 3.

14. (Currently amended) A compound according to ~~any one of claims 1-13~~claim 1, wherein T is a macrolide selected from the group consisting of:



and



or an *N*-oxide pharmaceutically acceptable salt, ester, or prodrug thereof, wherein M, R^{100}, R^{101}, R^{104}, R^{105}, R^{106}, R^{107}, R^{108}, R^{109}, R^{110}, and R^{120} are as described in claim 13.

15. (Currently amended) A compound according to ~~any one of claims 1-14~~claim 1, wherein T is a macrolide selected from the group consisting of:

3  ,  ,  ,

4  , 

5

6  ,  ,  ,

7

8 
,

9


,

10 
, 
,

11


,

12 
, 
,

13



and ;

or an *N*-oxide pharmaceutically acceptable salt, ester, or prodrug thereof,

wherein M, R^{100}, R^{101}, R^{102}, R^{104}, R^{109}, R^{114}, R^{126} and R^{127} are as described in claim 13.

16. (Currently amended) A compound according to ~~any one of claims 1-15~~claim 1, wherein T is a macrolide selected from the group consisting of:



,



,



,



,



,



,



,



, and



,

or an *N*-oxide pharmaceutically acceptable salt, ester, or prodrug thereof,

wherein M, R^1, R^2, R^{104}, R^{114}, R^{109} and R^{127} are as described in claim 13.

13

17. (Currently amended) A compound according to ~~any one of claims 1-16~~claim 1, wherein T is a macrolide selected from the group consisting of T1 through T33:



T1



T2



T3



T4



T5



T6



T7



T8



T9



T10



T11



T12



T13



T14



T15



T16



T17



T18



T19



T20



T21



T22 ;



T23



T24



T25



T26



T27



T28



T29



T30



T31



T32



T33

or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof.

18. (Original) A compound having the structure corresponding to any one of the structures listed in Table 1 or 13, or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof.

19. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1-18~~claim 1 and a pharmaceutically acceptable carrier.

20. (Currently amended) A method for treating or preventing a disease state in a mammal comprising administering to a mammal in need thereof an effective amount of a compound according to ~~any one of claims 1-18~~claim 1.

21. (Currently amended) A method of treating a microbial infection in a mammal comprising administering to the mammal an effective amount of a compound according to ~~any one of claims 1-18~~claim 1.

22. (Currently amended) A method of treating a fungal infection in a mammal comprising administering to the mammal an effective amount of a compound according to ~~any one of claims 1-18~~claim 1.

23. (Currently amended) A method of treating a parasitic disease in a mammal comprising administering to the mammal an effective amount of a compound according to ~~any one of claims 1-18~~claim 1.

24. (Currently amended) A method of treating a proliferative disease in a mammal comprising administering to the mammal an effective amount of a compound according to ~~any one of claims 1-18~~claim 1.

Misnumbered Claim 24. (Canceled)

Claims 25 – 31 (Canceled)

32. (New) A method of treating a viral infection in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1.

33. (New) A method of treating an inflammatory disease in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1.

34. (New) A method of treating a gastrointestinal motility disorder in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1.

35. (New) A method of treating or preventing a disease state in a mammal caused or mediated by a nonsense or missense mutation comprising administering to a mammal in need thereof an effective amount of a compound according to claim 1 to suppress expression of the nonsense or missense mutation.

36. (New) The method according to claim 20 wherein the compound is administered orally, parentally, or topically.

37. (New) A method of synthesizing a compound according to claim 1.

38. (New) A medical device containing a compound according to claim 1.

39. (New) The medical device according to claim 38, wherein the device is a stent.